Hodges Capital Management Inc. Acquires New Stake in DexCom, Inc. (NASDAQ:DXCM)

Hodges Capital Management Inc. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 2,500 shares of the medical device company’s stock, valued at approximately $347,000.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. KRS Capital Management LLC grew its position in shares of DexCom by 11.7% in the first quarter. KRS Capital Management LLC now owns 2,680 shares of the medical device company’s stock valued at $372,000 after purchasing an additional 280 shares during the period. Capital Insight Partners LLC raised its stake in shares of DexCom by 41.3% in the 1st quarter. Capital Insight Partners LLC now owns 3,600 shares of the medical device company’s stock valued at $499,000 after acquiring an additional 1,052 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in DexCom by 11.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 25,322 shares of the medical device company’s stock worth $3,512,000 after purchasing an additional 2,591 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new position in DexCom during the 1st quarter valued at about $258,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in DexCom during the 1st quarter worth approximately $2,808,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent analyst reports. UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Raymond James raised their price objective on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Citigroup increased their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, Canaccord Genuity Group increased their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $140.33.

DexCom Stock Down 1.0 %

Shares of DexCom stock traded down $1.16 on Friday, hitting $113.38. The company had a trading volume of 5,429,492 shares, compared to its average volume of 3,129,523. The stock has a 50 day moving average of $123.14 and a 200-day moving average of $125.66. The stock has a market capitalization of $45.09 billion, a price-to-earnings ratio of 73.15, a P/E/G ratio of 2.80 and a beta of 1.22. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, sell-side analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares in the company, valued at approximately $39,262,401.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the sale, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders sold 55,735 shares of company stock valued at $7,619,347 in the last 90 days. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.